Here are some sample widgets you could interact with from this dashboard:
ANALYSIS: Is Johnson & Johnson stock expensive based on a review of the fundamentals?
P/E Ratio: Based on trailing 2019 P/E ratios, JNJ stock looks attractive compared to prior years and comparable to Merck & Co, Inc
Johnson & Johnson 2019 trailing P/E ratio of 25.2 is 1.1x that of the 2019 Merck & Co, Inc P/E ratio of 23.3 $.
* P/E Ratio is calculated based on year end market price and trailing earnings. However, for 2020 P/E, we use 2019 earnings and current market price.
Historical Revenue Growth: Johnson & Johnson stock looks attractive compared to Merck & Co, Inc
Johnson & Johnson 2014-19 annualized revenue growth of 2% is 0.5x that of the 2014-19 S&P 500 annualized revenue growth rate of 3.9%.
2014-19 Annualized Revenue Growth Comparison
JNJ Annual Change in Revenue
MRK Annual Change In Revenue
Historical EPS Growth: Johnson & Johnson stock looks expensive compared to Merck & Co, Inc
Johnson & Johnson 2014-19 annualized EPS growth of 0% is -0.05x that of the 2014-19 S&P 500 annualized EPS growth rate of 5.7%.
2014-19 Annualized EPS Growth Comparison
JNJ Adjusted EPS Growth
MRK Adjusted EPS Growth
Survival Check: Total Debt Comparisons
Johnson & Johnson Total Debt has increased from $x to $y between 2016 and 2019. In comparison, Total Debt for Merck & Co, Inc has risen from $x to $y.
JNJ Total Debt
MRK Total Debt